Krystal Biotech (KRYS)
Krystal Biotech on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
2.9M
Short interest
settlement 2026-10-15
10.3
Days to cover
-0.9 days vs prior
83.6%
Short share of volume
2026-11-02
562
Fails to deliver
settlement 2026-10-14
Mon 11 Jan
Next earnings
estimated date
-$26.2M
Insider flow, 90 days
0 buys, 34 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in KRYS is 2,936,047 shares, down 227,595 shares over the last month. Over the last 48 readings it ranged from 2,367,240 shares (30 April 2025) to 3,699,397 shares (13 December 2024). At the reported average volume of 284K shares a day that is 10.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/krys" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,936,047 | -15.5% | 284,209 | 10.33 |
| 2026-09-30 | 3,475,527 | +9.9% | 310,502 | 11.19 |
| 2026-09-15 | 3,163,642 | -5.5% | 239,129 | 13.23 |
| 2026-08-31 | 3,347,813 | +4.5% | 219,245 | 15.27 |
| 2026-08-14 | 3,204,909 | +0.1% | 310,636 | 10.32 |
| 2026-07-31 | 3,202,260 | -8.4% | 770,966 | 4.15 |
| 2026-07-15 | 3,496,648 | -0.6% | 307,160 | 11.38 |
| 2026-06-30 | 3,517,595 | +12.1% | 489,255 | 7.19 |
| 2026-06-15 | 3,138,292 | -0.3% | 288,945 | 10.86 |
| 2026-05-29 | 3,147,863 | -1.1% | 194,305 | 16.20 |
| 2026-05-15 | 3,183,527 | +2.8% | 397,230 | 8.01 |
| 2026-04-30 | 3,095,771 | +6.3% | 225,020 | 13.76 |
| 2026-04-15 | 2,912,515 | -7.2% | 259,134 | 11.24 |
| 2026-03-31 | 3,136,891 | +8.6% | 313,299 | 10.01 |
| 2026-03-13 | 2,887,556 | -2.0% | 240,454 | 12.01 |
| 2026-02-27 | 2,947,930 | +6.9% | 363,479 | 8.11 |
| 2026-02-13 | 2,757,758 | +1.6% | 248,155 | 11.11 |
| 2026-01-30 | 2,713,674 | +2.1% | 267,773 | 10.13 |
| 2026-01-15 | 2,656,600 | -0.9% | 354,559 | 7.49 |
| 2025-12-31 | 2,680,099 | -1.5% | 258,746 | 10.36 |
| 2025-12-15 | 2,720,726 | -5.1% | 343,330 | 7.92 |
| 2025-11-28 | 2,867,935 | +0.1% | 222,787 | 12.87 |
| 2025-11-14 | 2,865,989 | -0.6% | 385,003 | 7.44 |
| 2025-10-31 | 2,882,886 | -0.2% | 267,125 | 10.79 |
| 2025-10-15 | 2,889,558 | -15.1% | 299,130 | 9.66 |
| 2025-09-30 | 3,403,495 | -5.6% | 365,600 | 9.31 |
| 2025-09-15 | 3,603,723 | +4.5% | 352,723 | 10.22 |
| 2025-08-29 | 3,447,590 | -1.0% | 232,272 | 14.84 |
| 2025-08-15 | 3,482,520 | +2.5% | 546,849 | 6.37 |
| 2025-07-31 | 3,397,667 | +8.1% | 281,396 | 12.07 |
| 2025-07-15 | 3,142,589 | -1.2% | 281,661 | 11.16 |
| 2025-06-30 | 3,180,398 | +4.8% | 450,052 | 7.07 |
| 2025-06-13 | 3,033,623 | +3.9% | 328,004 | 9.25 |
| 2025-05-30 | 2,921,085 | +12.3% | 352,852 | 8.28 |
| 2025-05-15 | 2,601,313 | +9.9% | 487,818 | 5.33 |
| 2025-04-30 | 2,367,240 | -2.1% | 247,600 | 9.56 |
| 2025-04-15 | 2,417,477 | -10.8% | 382,385 | 6.32 |
| 2025-03-31 | 2,711,754 | +0.4% | 256,378 | 10.58 |
| 2025-03-14 | 2,701,192 | -2.2% | 275,333 | 9.81 |
| 2025-02-28 | 2,761,745 | -13.3% | 361,888 | 7.63 |
| 2025-02-14 | 3,186,586 | +5.8% | 200,702 | 15.88 |
| 2025-01-31 | 3,011,606 | -7.4% | 205,479 | 14.66 |
| 2025-01-15 | 3,251,603 | -3.5% | 289,740 | 11.22 |
| 2024-12-31 | 3,369,689 | -8.9% | 302,873 | 11.13 |
| 2024-12-13 | 3,699,397 | +1.4% | 284,626 | 13.00 |
| 2024-11-29 | 3,650,087 | +1.3% | 199,377 | 18.31 |
| 2024-11-15 | 3,602,467 | +4.3% | 355,511 | 10.13 |
| 2024-10-31 | 3,453,822 | -2.4% | 130,795 | 26.41 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of KRYS volume is 83.6%, up 25.2 points over the last five sessions. Over the last 30 readings it ranged from 55.3% (28 October 2026) to 90.5% (12 October 2026). The latest reading is 10.0 points above the 30-session average of 73.6%, on 515K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 430K | 515K | 83.6% | 2,881 |
| 2026-10-30 | 94K | 117K | 80.4% | 0 |
| 2026-10-29 | 48K | 64K | 75.4% | 7 |
| 2026-10-28 | 50K | 91K | 55.3% | 0 |
| 2026-10-27 | 54K | 76K | 70.8% | 10 |
| 2026-10-26 | 59K | 102K | 58.4% | 0 |
| 2026-10-23 | 76K | 121K | 63.3% | 1 |
| 2026-10-22 | 55K | 84K | 65.9% | 0 |
| 2026-10-21 | 124K | 220K | 56.3% | 0 |
| 2026-10-20 | 50K | 69K | 72.9% | 0 |
| 2026-10-19 | 53K | 83K | 63.9% | 3 |
| 2026-10-16 | 74K | 93K | 79.5% | 5 |
| 2026-10-15 | 68K | 85K | 80.0% | 10 |
| 2026-10-14 | 64K | 85K | 74.7% | 0 |
| 2026-10-13 | 64K | 91K | 69.9% | 5 |
| 2026-10-12 | 63K | 69K | 90.5% | 0 |
| 2026-10-09 | 58K | 70K | 81.9% | 0 |
| 2026-10-08 | 78K | 103K | 75.5% | 29 |
| 2026-10-07 | 100K | 129K | 77.6% | 0 |
| 2026-10-06 | 124K | 161K | 77.1% | 0 |
| 2026-10-05 | 80K | 111K | 71.5% | 160 |
| 2026-10-02 | 106K | 177K | 60.0% | 1 |
| 2026-10-01 | 71K | 99K | 71.7% | 152 |
| 2026-09-30 | 56K | 75K | 74.8% | 0 |
| 2026-09-29 | 59K | 75K | 79.2% | 0 |
| 2026-09-28 | 63K | 94K | 67.1% | 0 |
| 2026-09-25 | 53K | 66K | 81.1% | 1 |
| 2026-09-24 | 68K | 77K | 87.5% | 40 |
| 2026-09-23 | 56K | 67K | 83.7% | 0 |
| 2026-09-22 | 62K | 80K | 77.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in KRYS is 562 shares, up 447 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (12 June 2026) to 12,862 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 562 | $321.16 | $180K |
| 2026-10-09 | 115 | $327.30 | $38K |
| 2026-09-18 | 10 | $338.75 | $3K |
| 2026-09-17 | 462 | $336.67 | $156K |
| 2026-09-09 | 7,408 | $351.26 | $2.6M |
| 2026-09-04 | 203 | $371.47 | $75K |
| 2026-09-03 | 643 | $369.23 | $237K |
| 2026-09-01 | 231 | $359.36 | $83K |
| 2026-08-21 | 523 | $337.02 | $176K |
| 2026-08-14 | 1,767 | $328.34 | $580K |
| 2026-08-07 | 90 | $322.69 | $29K |
| 2026-08-04 | 559 | $312.57 | $175K |
| 2026-07-31 | 168 | $366.85 | $62K |
| 2026-07-30 | 3,245 | $363.28 | $1.2M |
| 2026-07-29 | 6,230 | $364.23 | $2.3M |
| 2026-07-27 | 9 | $335.19 | $3K |
| 2026-07-16 | 992 | $350.24 | $347K |
| 2026-07-15 | 86 | $339.43 | $29K |
| 2026-07-14 | 5 | $363.44 | $2K |
| 2026-07-09 | 80 | $375.40 | $30K |
| 2026-07-08 | 19 | $368.60 | $7K |
| 2026-07-01 | 8 | $371.67 | $3K |
| 2026-06-30 | 12,862 | $378.15 | $4.9M |
| 2026-06-29 | 97 | $372.25 | $36K |
| 2026-06-26 | 431 | $359.93 | $155K |
| 2026-06-18 | 3,325 | $341.66 | $1.1M |
| 2026-06-15 | 967 | $317.97 | $307K |
| 2026-06-12 | 4 | $321.55 | $1K |
| 2026-06-11 | 336 | $312.41 | $105K |
| 2026-06-09 | 11 | $301.76 | $3K |
Insider trades
SEC Form 4, newest first. JSONInsiders at KRYS reported 34 open-market sells worth $26.2M in the last 90 days and no open-market buys. Latest filing: Krishnan Suma (President, R&D) on 2026-09-04.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 399 | $366.56 | $146K | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 826 | $365.41 | $302K | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 1K | $364.48 | $484K | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 565 | $363.34 | $205K | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 2K | $362.65 | $722K | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 1K | $361.61 | $449K | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 2K | $360.47 | $836K | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 3K | $359.39 | $1.2M | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 3K | $358.42 | $1.1M | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 4K | $357.57 | $1.4M | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 3K | $356.37 | $1.2M | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 2K | $355.57 | $713K | 1.3M |
| 2026-09-04 | Krishnan Suma | President, R&D | Sell | 520 | $354.54 | $184K | 1.3M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 405 | $366.56 | $148K | 1.3M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 847 | $365.42 | $310K | 1.3M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 1K | $364.48 | $495K | 1.3M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 573 | $363.34 | $208K | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 2K | $362.65 | $729K | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 1K | $361.61 | $439K | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 2K | $360.46 | $817K | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 3K | $359.39 | $1.2M | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 3K | $358.42 | $1.1M | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 4K | $357.57 | $1.4M | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 3K | $356.37 | $1.2M | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 2K | $355.57 | $721K | 1.4M |
| 2026-09-04 | Krishnan Krish S | President and CEO | Sell | 520 | $354.54 | $184K | 1.4M |
| 2026-08-14 | ROSSI DINO A | Director | Sell | 40 | $333.23 | $13K | 50K |
| 2026-08-14 | ROSSI DINO A | Director | Sell | 3K | $331.43 | $1.0M | 50K |
| 2026-08-14 | ROSSI DINO A | Director | Sell | 5K | $330.36 | $1.6M | 53K |
| 2026-08-14 | ROSSI DINO A | Director | Sell | 7K | $329.60 | $2.4M | 58K |
| 2026-08-14 | ROSSI DINO A | Director | Sell | 2K | $328.52 | $554K | 65K |
| 2026-08-14 | ROSSI DINO A | Director | Sell | 5K | $327.39 | $1.7M | 67K |
| 2026-08-14 | ROSSI DINO A | Director | Sell | 2K | $326.60 | $747K | 72K |
| 2026-08-14 | ROSSI DINO A | Director | Sell | 341 | $325.60 | $111K | 75K |
| 2026-08-14 | ROSSI DINO A | Director | Gift | 4K | $0.00 | $0 | 75K |
| 2026-06-25 | Thomas John Charles | EVP, General Counsel | Exercise or conversion | 1K | $179.25 | $179K | 1K |
| 2026-06-25 | Thomas John Charles | EVP, General Counsel | Sell | 1K | $347.27 | $347K | 0 |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 240 | $311.65 | $75K | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 2K | $310.94 | $634K | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 3K | $309.95 | $868K | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 4K | $308.89 | $1.2M | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 13K | $307.81 | $3.9M | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 1K | $307.09 | $414K | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 480 | $305.87 | $147K | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 400 | $304.89 | $122K | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 247 | $303.17 | $75K | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 593 | $302.25 | $179K | 1.4M |
| 2026-06-04 | Krishnan Suma | President, R&D | Sell | 320 | $300.75 | $96K | 1.4M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 40 | $312.23 | $12K | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 964 | $311.36 | $300K | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 3K | $310.43 | $823K | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 3K | $309.49 | $862K | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 5K | $308.47 | $1.5M | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 11K | $307.68 | $3.5M | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 589 | $306.33 | $180K | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 544 | $304.81 | $166K | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 176 | $303.17 | $53K | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 640 | $302.24 | $193K | 1.5M |
| 2026-06-04 | Krishnan Krish S | President and CEO | Sell | 320 | $300.75 | $96K | 1.5M |
| 2026-05-26 | Thomas John Charles | EVP, General Counsel | Sell | 642 | $302.03 | $194K | 0 |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 2K | $266.42 | $453K | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 6K | $265.16 | $1.6M | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 5K | $264.64 | $1.3M | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 2K | $263.58 | $593K | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 2K | $262.35 | $508K | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 3K | $261.41 | $766K | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 4K | $260.37 | $955K | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 668 | $259.61 | $173K | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 589 | $258.54 | $152K | 1.4M |
| 2026-03-04 | Krishnan Suma | President, R&D | Sell | 407 | $257.32 | $105K | 1.4M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 920 | $266.56 | $245K | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 2K | $265.59 | $648K | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 9K | $264.85 | $2.3M | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 2K | $263.70 | $539K | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 2K | $262.44 | $625K | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 3K | $261.41 | $774K | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 3K | $260.49 | $815K | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 1K | $259.87 | $358K | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 470 | $258.38 | $121K | 1.5M |
| 2026-03-04 | Krishnan Krish S | President and CEO | Sell | 483 | $257.31 | $124K | 1.5M |
| 2026-03-02 | ROMANO KATHRYN | Chief Accounting Officer | Sell | 750 | $267.60 | $201K | 22K |
| 2026-02-27 | ROMANO KATHRYN | Chief Accounting Officer | Tax withholding | 240 | $275.64 | $66K | 23K |
| 2026-02-27 | ROMANO KATHRYN | Chief Accounting Officer | Exercise or conversion | 550 | $0.00 | $0 | 23K |
| 2026-02-27 | ROMANO KATHRYN | Chief Accounting Officer | Tax withholding | 3K | $275.64 | $899K | 23K |
| 2026-02-27 | ROMANO KATHRYN | Chief Accounting Officer | Exercise or conversion | 8K | $0.00 | $0 | 26K |
| 2026-02-27 | Krishnan Suma | President, R&D | Tax withholding | 3K | $275.64 | $718K | 1.5M |
| 2026-02-27 | Krishnan Suma | President, R&D | Exercise or conversion | 6K | $0.00 | $0 | 1.5M |
| 2026-02-27 | Krishnan Suma | President, R&D | Tax withholding | 12K | $275.64 | $3.3M | 1.5M |
| 2026-02-27 | Krishnan Suma | President, R&D | Exercise or conversion | 26K | $0.00 | $0 | 1.5M |
| 2026-02-27 | Krishnan Suma | President, R&D | Tax withholding | 4K | $275.64 | $1.1M | 1.5M |
| 2026-02-27 | Krishnan Suma | President, R&D | Exercise or conversion | 9K | $0.00 | $0 | 1.5M |
| 2026-02-27 | Krishnan Suma | President, R&D | Tax withholding | 2K | $275.64 | $502K | 1.4M |
| 2026-02-27 | Krishnan Suma | President, R&D | Exercise or conversion | 4K | $0.00 | $0 | 1.4M |
| 2026-02-27 | Krishnan Suma | President, R&D | Tax withholding | 10K | $275.64 | $2.8M | 1.4M |
| 2026-02-27 | Krishnan Suma | President, R&D | Exercise or conversion | 23K | $0.00 | $0 | 1.4M |
| 2026-02-27 | Krishnan Krish S | President and CEO | Tax withholding | 2K | $275.64 | $502K | 1.4M |
| 2026-02-27 | Krishnan Krish S | President and CEO | Exercise or conversion | 4K | $0.00 | $0 | 1.4M |
| 2026-02-27 | Krishnan Krish S | President and CEO | Tax withholding | 10K | $275.64 | $2.8M | 1.4M |
| 2026-02-27 | Krishnan Krish S | President and CEO | Exercise or conversion | 23K | $0.00 | $0 | 1.4M |
| 2026-02-27 | Krishnan Krish S | President and CEO | Tax withholding | 3K | $275.64 | $718K | 1.5M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON18 Form 144 notices on file for KRYS worth $86.3M at the prices reported; 2 in the last 90 days worth $18.6M. Latest: SUMA KRISHNAN filed on 2026-09-04 to sell 25,000 shares ($9.3M) from 2026-09-04.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-04 | SUMA KRISHNANDirector, Officer, 10% Stockholder | 25K | $9.3M | 0.084% | 2026-09-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-04 | KRISH KRISHNANDirector, Officer, 10% Stockholder | 25K | $9.3M | 0.084% | 2026-09-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-25 | Thomas John CharlesOfficer | 1K | $347K | 0.003% | 2026-06-25 | Fidelity Brokerage Services LLC |
| 2026-06-04 | SUMA KRISHNANDirector, Officer, 10% Stockholder | 25K | $7.5M | 0.085% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | KRISH KRISHNANDirector, Officer, 10% Stockholder | 25K | $7.5M | 0.085% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | Thomas John CharlesOfficer | 642 | $194K | 0.002% | 2026-05-26 | Fidelity Brokerage Services LLC |
| 2026-03-04 | SUMA KRISHNANDirector, Officer, 10% Stockholder | 25K | $6.6M | 0.086% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | KRISH KRISHNANDirector, Officer, 10% Stockholder | 25K | $6.6M | 0.086% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | ROMANO KATHRYNOfficer | 750 | $201K | 0.003% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-02-27 | Daniel S JanneyDirector | 12K | $3.3M | 0.040% | 2026-02-27 | Merrill Lynch |
| 2026-02-26 | Daniel S JanneyDirector | 8K | $2.1M | 0.026% | 2026-02-26 | Merrill Lynch |
| 2026-02-25 | Daniel S JanneyDirector | 700 | $193K | 0.002% | 2026-02-25 | Merrill Lynch |
| 2026-02-24 | JANNEY DANIELDirector | 38K | $10.1M | 0.130% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Daniel S JanneyDirector | 14K | $3.7M | 0.047% | 2026-02-24 | Merrill Lynch |
| 2026-02-19 | ROSSI DINO ADirector | 19K | $5.0M | 0.065% | 2026-02-19 | Fidelity Brokerage Services LLC |
| 2026-02-09 | ROMANO KATHRYNOfficer | 13K | $3.5M | 0.043% | 2026-02-09 | Fidelity Brokerage Services LLC |
| 2025-12-04 | SUMA KRISHNANDirector, Officer, 10% Stockholder | 25K | $5.4M | 0.086% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | KRISH KRISHNANDirector, Officer, 10% Stockholder | 25K | $5.4M | 0.086% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of KRYS in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 11.6% of the class (3,427,645 shares), filed 2026-10-27 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-30 | 13G/Ano. 1 | Vanguard Portfolio Managementinvestment adviser | 1.3M | 4.4% | 2026-09-30 |
| 2026-10-27 | 13G/Ano. 5 | BlackRock, Inc.parent holding company | 3.4M | 11.6% | 2026-09-30 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding KRYS at their latest 13F. JSON6 of the 30 tracked managers held KRYS at their latest 13F, $61.2M in total at quarter-end prices. Renaissance Technologies is the largest at $22.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 60K | $22.2M | 0.03% | +50K |
| Bridgewater Associates | 2026-06-30 | 54K | $20.3M | 0.08% | +8K |
| Fisher Asset Management | 2026-06-30 | 28K | $10.3M | 0.00% | -108 |
| AQR Capital Management | 2026-06-30 | 14K | $5.2M | 0.00% | -112 |
| Two Sigma Investments | 2026-06-30 | 6K | $2.3M | 0.00% | new |
| Citadel Advisors | 2026-06-30 | 3K | $1.0M | 0.00% | -1 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Krystal Biotech reported revenue of $119.2M, up 24.1% from the same quarter a year earlier, and net income of $54.8M (1.79 diluted EPS). In FY 2025 it generated $200.9M of operating cash flow.
- Cash
- $427.7M
- Equity
- $1.36B
- Total assets
- $1.50B
- Shares outstanding
- 29,598,836
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $119.2M | $54.8M | 45.9% | 1.79 |
| Q1 FY 2026 | 2026-03-31 | $116.4M | $55.9M | 48.1% | 1.83 |
| Q4 FY 2025derived | 2025-12-31 | $107.1M | $51.4M | 48.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $97.8M | $79.4M | 81.2% | 2.66 |
| Q2 FY 2025 | 2025-06-30 | $96.0M | $38.3M | 39.9% | 1.29 |
| Q1 FY 2025 | 2025-03-31 | $88.2M | $35.7M | 40.5% | 1.20 |
| Q4 FY 2024derived | 2024-12-31 | $91.1M | $45.5M | 49.9% | n/a |
| Q3 FY 2024 | 2024-09-30 | $83.8M | $27.2M | 32.4% | 0.91 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $389.1M | $204.8M | $200.9M | $12.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $290.5M | $89.2M | $123.4M | $4.2M | n/a | n/a |
| FY 2023 | 2023-12-31 | $50.7M | $10.9M | -$88.8M | $11.8M | n/a | n/a |
| FY 2022 | 2022-12-31 | $0 | -$140.0M | -$100.6M | $53.0M | n/a | n/a |
| FY 2021 | 2021-12-31 | $0 | -$69.6M | -$47.9M | $68.3M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-28 from the cover page.
What this page is
Krystal Biotech in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Krystal Biotech (KRYS), SEC CIK 1711279, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-04.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-11-02.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-04.JSON and CSV
- Company record
- EDGAR filing index for CIK 1711279Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of KRYS is sold short?
2,936,047 shares were held short at the 2026-10-15 settlement, 10.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is KRYS's daily short volume?
On 2026-11-02, 430,319 of the 514,877 KRYS shares reported to FINRA were sold short, 83.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does KRYS have fails to deliver?
The SEC's latest file shows 562 KRYS shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are KRYS insiders buying or selling?
Insiders at KRYS reported 34 open-market sells worth $26.2M in the last 90 days and no open-market buys. Latest filing: Krishnan Suma (President, R&D) on 2026-09-04.
Have KRYS insiders filed to sell?
18 Form 144 notices on file for KRYS worth $86.3M at the prices reported; 2 in the last 90 days worth $18.6M. Latest: SUMA KRISHNAN filed on 2026-09-04 to sell 25,000 shares ($9.3M) from 2026-09-04.
Who owns 5% or more of KRYS?
1 holder reports 5% or more of KRYS in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 11.6% of the class (3,427,645 shares), filed 2026-10-27 for an event on 2026-09-30.
What did KRYS report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Krystal Biotech reported revenue of $119.2M, up 24.1% from the same quarter a year earlier, and net income of $54.8M (1.79 diluted EPS). In FY 2025 it generated $200.9M of operating cash flow.
Which tracked 13F managers own KRYS?
6 of the 30 tracked 13F managers held KRYS shares at their latest filing, $61.2M in all. The largest: Renaissance Technologies (60K shares, $22.2M), Ray Dalio's Bridgewater Associates (54K shares, $20.3M), Ken Fisher's Fisher Asset Management (28K shares, $10.3M), Cliff Asness's AQR Capital Management (14K shares, $5.2M), Two Sigma Investments (6K shares, $2.3M), Ken Griffin's Citadel Advisors (3K shares, $1.0M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.